MRK

Business Context and Reporting Period

This summary covers the Form 10-Q filed by Schering-Plough Corporation for the quarterly period ended March 31, 2003. The company is a global pharmaceutical and consumer health products manufacturer. The reporting period was significantly impacted by the loss of U.S. market exclusivity for its key allergy product, CLARITIN, which was converted to over-the-counter (OTC) status in December 2002, and ongoing regulatory challenges regarding manufacturing practices.

Key Financial Metrics

Note: Gross margin calculated as (Net Sales - Cost of Sales) / Net Sales.

Material Changes vs. Prior Period

• Sales Decline: Consolidated net sales dropped 19% year-over-year, driven primarily by a 55% decline in Allergy & Respiratory sales. U.S. prescription CLARITIN sales plummeted from $565 million in Q1 2002 to $16 million in Q1 2003 due to the switch to OTC status and the company's decision to delay revenue recognition until patient prescriptions are filled.
• Profitability Compression: Income before taxes fell 72% to $216 million. Cost of sales as a percentage of sales increased to 31.7% from 22.6% due to product mix changes and higher manufacturing costs associated with Good Manufacturing Practices (CGMP) compliance.
• Expense Increases: Selling, general, and administrative (SG&A) expenses rose as a percentage of sales to 40.6% (from 35.9%) due to lower sales volumes and promotional efforts for new products like CLARINEX and ZETIA. R&D spending increased 13% to $344 million.
• Cash Flow: While operating cash flow decreased, it was supported by the collection of accounts receivable following the CLARITIN business decline. However, management notes that future quarters may not see this mitigation effect.

Outlook, Risks, and Contingencies

• Liquidity Concerns: Management warns that cash flow from operations in subsequent quarters of 2003 may not be sufficient to fund working capital, capital expenditures, and dividends without additional borrowings. A $250 million installment of the FDA consent decree payment is due in Q2 2003.
• Consent Decree: The company is under a consent decree with the FDA regarding CGMP compliance at facilities in New Jersey and Puerto Rico. Failure to meet deadlines could result in daily penalties up to $15,000 per day (capped at $50 million/year) and potential production halts. A second $250 million payment is due in Q2 2003.
• Legal Reserves: In February 2003, the company increased litigation reserves by $150 million related to investigations by U.S. Attorney's Offices regarding marketing practices, Medicaid rebates, and Average Wholesale Price (AWP) reporting. The company cannot predict the ultimate financial impact of these investigations.
• Patent Litigation: A federal court ruled certain desloratadine patent claims (protecting CLARITIN) invalid; the company has appealed. Generic entry for REBETOL is expected in 2003 following licensing settlements with Three Rivers, Geneva, and Teva.
• Collaboration: Alliance revenue from the Merck collaboration (ZETIA) was insignificant in Q1 2003 due to launch-related marketing expenses.

Investor Verification Checklist

• CLARITIN Transition: Verify the trajectory of OTC CLARITIN sales versus the decline in prescription sales and the impact on the CLARINEX franchise.
• Consent Decree Compliance: Monitor the status of CGMP Work Plans and revalidation programs to assess the risk of additional penalties or production stoppages.
• Litigation Exposure: Review updates on the $150 million litigation reserve and the status of investigations into marketing practices and AWP reporting.
• Liquidity Strategy: Confirm the company's ability to access the $1 billion in committed credit facilities or the $2 billion shelf registration to fund the Q2 consent decree payment and ongoing operations.
• Patent Appeals: Track the appeal of the desloratadine patent invalidity ruling, as a loss could accelerate generic competition for CLARITIN.